BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega, Marta Burrel, Ángeles Garcia-Criado, Robin K. Kelley, Peter R. Galle, Vincenzo Mazzaferro, Riad Salem, Bruno Sangro, Amit G. Singal, Arndt Vogel, Josep Fuster, Carmen Ayuso, Jordi Bruix

Research output: Contribution to journalReview articlepeer-review

805 Scopus citations


There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

Original languageEnglish (US)
Pages (from-to)681-693
Number of pages13
JournalJournal of Hepatology
Issue number3
StatePublished - Mar 2022


  • AFP
  • ALBI score
  • BCLC
  • HCC
  • TARE
  • ablation
  • liver transplantation TACE
  • surgery
  • survival
  • systemic treatment

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update'. Together they form a unique fingerprint.

Cite this